Skip to main content
SpringerLink
Log in

The Malignant Lymphomas

  • Chapter
Cancer Metastasis, Molecular and Cellular Mechanisms and Clinical Intervention

Part of the book series: Cancer Metastasis — Biology and Treatment ((CMBT,volume 1))

  • 186 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hodgkin T. On some morbid appearances of the absorbant glands and spleen. Medic-Chirugical Transactions 1832 17:68–114.

    Google Scholar 

  2. Harris NL., Jaffe ES., Stein H., Banks PM., Chan JKC, Cleary ML, Delsol G, DeWolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri S, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 1994 84: 1361–1392.

    PubMed  CAS  Google Scholar 

  3. Jaffe ES., Harris NL., Diebold J., Muller-Hermelink HK. World Health Organisation classification of Neoplastic Diseases of the Haematopoietic and lymphoid tissues. Am.J. Clin. Pathol. 1999 (Suppl 1) S8–S12.

    Google Scholar 

  4. Devasa SS., Silverman DT., Young JL, Pollack ES, Brown CC, Horn JW, Percy CL, Myers MH, McKay FW, Fraumeni JF. Current incidence and mortality trends among whites in the United States 1947–1984. J. Natl Cancer Inst. 1987 79:701–770.

    Google Scholar 

  5. Frizzera G., Wu D., Inghirami G.The usefulness of Immunophenotypic and Genotypic studies in the diagnosis and classification of haematopoietic andlymphoid neoplasms.An update. Am.J. Clin. Path. 1999 (Suppl 1) S13–S39.

    Google Scholar 

  6. Limpens J., Stad R., Vos C, de Vlaam C, de Jong D, van Ommen G-JB, Schuuring E, Kluin PM. Lymphomaassociated translocations t(14;18) in blood B-cells of normal individuals. Blood 1995 85:2528–2536.

    PubMed  CAS  Google Scholar 

  7. Wiemels J., Cazzaniga G., Daniotti M., Eden OB., Addison GM., Masera G., Saha V., Biondi A & Greaves M. Prenatal origin of acute lymphoblastic leukaemia in children.

    Google Scholar 

  8. Liu Y., Hernandez AM., Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc. Natl. Acad. Sci. USA.,1994 91: 8910–8914.

    PubMed  CAS  Google Scholar 

  9. Osmond D.G. B-cell development in bone marrow. Semin Immunol 1990 2:173–180

    PubMed  CAS  Google Scholar 

  10. Brandtzaeg P., Farstad I.N. and Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunology Today 1999 20: 247–290

    Google Scholar 

  11. Freedman A.S. Nadler L.M. Immunologic markers in non-Hodgkin’s Lymphoma. Hematology-Oncology Clinics of North America 1991 5: 871–879.

    CAS  Google Scholar 

  12. Picker L.J., Butcher E.G. Physiological and molecular mechanisms of lymphocyte homing. Ann Rev Immunol 1992 10: 561–591.

    Article  CAS  Google Scholar 

  13. Reth M., Hornback J., Wienands J, Campbell KS, Chien N, Justenert LB, Cambier JC. The B-cell antigen receptor complex.Immunology Today 1991 12: 196–201

    Article  PubMed  CAS  Google Scholar 

  14. Springer T.A.Traffic signals for lymphocyte recirculation and leucocyte emigration:The multistep paradigm (Review).Cell 1994 76: 301–314.

    Article  PubMed  CAS  Google Scholar 

  15. Rolink A. Melches F. Molecular and cellular origin of B lymphocyte diversity. Cell 1991 66: 1081–1094.

    Article  PubMed  CAS  Google Scholar 

  16. Melchers F., Karasuyama H., Haasner D, Bauer S, Kudo A, Sakaguchi N, Jameson B, Rolink A. The surrogate light chain in B-cell development. Immunology Today 1993 14: 60–68

    Article  PubMed  CAS  Google Scholar 

  17. Negative signalling in B-cells.SHIP Grbs shc. Tridandapan, S., Kelley T., Cooney D., Pradham M., Coggeshall K.M. Immunology Today 1997 18: 424–427

    Google Scholar 

  18. Noesel C, van Miedema F., Brouwer M, de Rie MA, Aarden LA, van Lier RAW. Regulatory propertiesof LFA1-alpha and beta chain inlymphocyte activation. Nature 1988 333: 850–852

    PubMed  Google Scholar 

  19. Lin Y-J., Johnson G.D., Gordon J, MacLennan ICM. Germinal centres in T-celldependent antibody responses. Immunology Today 1992 13: 17–21.

    Google Scholar 

  20. Koopman G., Keehnen R.M.J., Lindhout E.et al. Adhesion through the LFA-1 (CD 11 a/CD 18)-ICAM-1 (CD54) and the VLA4(CD49d)-VCAM-1 (CD 106) pathways prevents opoptosis of germinal centreB-cells. J. Immunol. 1994 152: 3760–3768

    PubMed  CAS  Google Scholar 

  21. Lindhart E., Koopman G., Pals S.T., de Groot C. Triplecheck for antigen specificity of B-cells during germinal centre reactions. Immunology Today 1997 12: 573–577.

    Google Scholar 

  22. Hardy R.R., Hayakawa K. CDS B-cells, a fetal B-celllineage. Adv. Immunol. 1994 55: 297–339.

    PubMed  CAS  Google Scholar 

  23. Shipp M. Harrington D. The International Non-Hodgkin’s Lymphoma Progostic Factors Project: Apredictive model for aggressive non-Hodgkin’s Lymphoma. N Engl J Med 1993 329: 987–994

    Google Scholar 

  24. Gianni A.M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P., Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997 336:1290–1297

    Article  PubMed  CAS  Google Scholar 

  25. Haioun C., Lepage E., Gisselbrecht C.et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-gradenon-Hodgkin’s lymphoma in first complete remission: astudy of 464 patients. J Clin Oncol 1994 12: 2543.

    PubMed  CAS  Google Scholar 

  26. Haioun C., Lepage E., Gisselbrecht C. et al. Benefits of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH87-2.J Clin Oncol 1997 15:1131.

    PubMed  CAS  Google Scholar 

  27. Santini G., Salvagno L., Leoni P.et al. VACOP-B vs VACOP-Bplus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the Non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 1998 16: 2796–2802.

    PubMed  CAS  Google Scholar 

  28. Reyes F., Lepage E., Morel P, Lederlin B, Coiffier H, Tilly A, Bosly J, Gabarre J, Briere J, Fillet G, Molina T, Gisselbrecht C. Failure of first-lineinductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updatedresults of the randomized LNH93-3study. Blood 1997 90:(Suppl 1) 594a.(Abstract 2640)

    Google Scholar 

  29. Kaiser U., Ubelacher I., Horeman K. on behalf of the Gernam High Grade Lymphoma Study Group, Marburg, Germany. High dose chemotherapy with autologous stem cell transplantation in high grade NHL.First analysis of arandomized multicentre study. Bone Marrow Transplant 1998 21:(Suppl 1) 5117.

    Google Scholar 

  30. Blay J-Y, Gomez F, Seblan C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T. The International Prognostic Index correlates to survival in patients with aggressivelymphoma inrelapse: analysis of the PARMA trial. Parma Group. Blood 1998 92: 3562–8.

    CAS  Google Scholar 

  31. Zwicky C.S., Maddocks A.B. Andeven N., Gribben J.G. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in Non Hodgkin’s Lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996 88: 3314–3322.

    PubMed  CAS  Google Scholar 

  32. Nadler L.M., Stastenko P., Hardy R., Kaplan W.D., Britton L.N., Kafe D.W. Antman K.I., Schlossman S.F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.Cancer Res. 1980 40: 3147–3154.

    PubMed  CAS  Google Scholar 

  33. Thielman K., Maloney D.G., Meeker T., Fujimoto J., Doss C., Warnke R.A., Bindl J., Gralow J., Miller R.A., Levy R. Strategies for production of monoclonal anti idiotype antibodies against tumour B-cell lymphomas. J. Immunol 1984 133: 495–501.

    Google Scholar 

  34. Lundin J., Osterborg A., Brittinger G., Crowther D., Dombret H., Engert A., Epenetos A., Gisselbrecht C., Huln D., Jaeger U., Thomas T., Marcus R., Nissen N., Poynton C., Rankin E., Stehel R., Uppenkamp M., Willemze R., Mellstedt H. CAMPATH 1H monoclonal antibody in therapy for previously treated low grade Non hodgkin’s Lymphoma: A phase II multicentre study, European Sutdy Group of CAMPATH-1 treatment in low grade grade Non Hodgkin’s Lymphoma. J Clin Oncol 1998 16: 3257–3263.

    PubMed  CAS  Google Scholar 

  35. Osterborg A., Dyer M.T., Bunjes D., Pangolis G.A., Bastion Y., Catovsky D., MellstedtH. PhaseII multi centre study of human CD52 antibody in previously treated Chronic lymphocytic leukaemia. European Study Group of CAMPATH-1H treated in Chronic lymphocytic leukaemia. J Clin Oncol 1997 15: 1567–1574.

    PubMed  CAS  Google Scholar 

  36. McLaughlin P., Grillo-Lopez P, Link B.K., Levy R., Czuczman M., Williams M., Heyman M.R.et al. Rituximab chimeric anti CD20 monoclonal antibody therapy for relapsed indolentlymphoma. Half of patientsrespond to a four dose treatment program. J Clin Oncol 16;19982825.

    Google Scholar 

  37. van de Winkel J.G.J., Bast B., de Gast G.C. Immunotherapeutic potential of bispecific antibodies.Immunology Today 1997 12:562–564

    Google Scholar 

  38. Renner C., Jung W., Sahin U, Denfield R, Pohl C, Trumper L, Hartman F, van Lier R, Pfreundschuh M. Cure of xenografted human tumours by bispecific monoclonal antibodies and human T-cells. Science 1994 264:833–835

    PubMed  CAS  Google Scholar 

  39. Hartmann F., Renner C., Jung W, Diesting C, Juwana M, Eichenkopf B, Kloft M, Pfreundschuh M. Treatment of refractory Hodgkin’s Disease with an anti CD16-CD30 bispecific antibody. Blood 1997 89:2042–204

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Christopher H. Poynton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Wales College of Medicine, UK

    Wen G. Jiang  & Robert E. Mansel  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Kluwer Academic Publishers

About this chapter

Cite this chapter

Poynton, C.H. (2000). The Malignant Lymphomas. In: Jiang, W.G., Mansel, R.E. (eds) Cancer Metastasis, Molecular and Cellular Mechanisms and Clinical Intervention. Cancer Metastasis — Biology and Treatment, vol 1. Springer, Dordrecht. https://doi.org/10.1007/0-306-48388-2_14

Download citation

  • DOI: https://doi.org/10.1007/0-306-48388-2_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-0-7923-6395-8

  • Online ISBN: 978-0-306-48388-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation